Email us connect@hepdconnect.org
Welcome to Hepatitis Delta Connect!
A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected.
Clinical Trial Finder - Find A Clinical Trial Near You!
Watch our latest webinar!
We would love to hear from you! Complete the survey to sign up!
Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today!
We've educated 13,000 people in 111 countries!
News & Updates
March 2021 Blog Post: Hepatitis B and Hepatitis Delta
January 2021 Blog Post: Eiger Presents Clinical Trial Results at The Liver Meeting Digital Experience™ 2020
September 2020 Blog Post: New Hepatitis Delta Treatment Approved by European Commission
May 2020 Blog Post: Does Hepatitis Delta Increase My Risk for Liver Cancer?
View our recent webinar, Hepatitis Delta Treatment Endpoints: How Do We Measure Success in the Era of Emerging Therapies? recording here.
01/04/2022: New Slideset Updated on Don't Delay with Delta: Best Practices and Calls to Action in HDV
12/21/2021: Bulevirtide Improves Quality of Life in Chronic HDV
12/21/2021: Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection
12/20/2021: Medical Minutes Podcasts on HDV Epidemiology and Universal Screening
12/18/2021: Large Proportion of Undiagnosed Anti-HDV Positive Individuals Due to Lack of Testing
12/16/2021: UN Introduces Resolution on Rare Diseases
12/13/2021: Bulevirtide Shows Real-World Efficacy Versus HDV
12/03/2021: Should We Screen All Patients with Hepatitis B for Hepatitis Delta?
12/01/2021: Hepatitis Delta Presentations from the 2021 AASLD Liver Meeting Now Available
12/01/2021: Ethnic Variations in Clinical Presentation and Treatment Eligibility for HDV Infection at a US Referral Center
11/19/2021: Gilead Files BLA for Bulevirtide to Treat Chronic HDV Infection
11/12/2021: Prevalence and Characteristics of Hepatitis Delta in the United States: An Analysis of All-Payer Claims Databases
09/29/2021: The Kinesin KIF4 Mediates HBV/HDV Entry Through Regulation of Surface NTCP Localization and Can Be Targeted by RXR Agonists in vitro
08/24/2021: The Highly Complementary Model of Hepatitis D and Hepatitis B, Described by Scientists, Can Broadly Cover the HDV Replication Cycle
07/28/2021: Hepatitis D: Neglected Disease in the Race to Eliminate Viral Hepatitis by 2030
07/27/2021: Risk of Hepatocellular Carcinoma in Hepatitis B & D Virus Co-Infected Patients: A Systematic Review and Meta-Analysis of Longitudinal Studies
07/12/2021: Significant Disparities in the International Incidence of Hepatitis Delta Virus
06/25/2021: Gilead Preps Filing for Hepatitis D Therapy Hepcludex in US
06/24/2021: Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
04/01/2021: Hepatitis Delta Infection Among Persons with HIV in Europe
Get Connected
